Hualan Biological Vaccine Inc. (SHE:301207)

Market Cap	11.85B +12.7%
Revenue (ttm)	1.20B +6.6%
Net Income	182.92M -11.0%
EPS	0.31 -10.5%
Shares Out	595.00M
PE Ratio	64.77
Forward PE	55.31
Dividend	1.60 (8.04%)
Ex-Dividend Date	Oct 27, 2025

Volume	4,948,977
Average Volume	6,256,825
Open	19.95
Previous Close	20.11
Day's Range	19.68 - 20.09
52-Week Range	15.41 - 27.88
Beta	0.77
RSI	51.29
Earnings Date	Mar 28, 2026

About Hualan Biological Vaccine

Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetically engineered biological products in China. The company’s main products include influenza virus split vaccine, quadrivalent influenza virus split vaccine, quadrivalent influenza virus split vaccine (pediatric formulation), H1N1 influenza A virus split vaccine, ACYW135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hansenula polymorpha), group A and C meningococcal polysaccharide vaccine, freeze-drie...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 748
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301207

Financial Performance

In 2025, Hualan Biological Vaccine's revenue was 1.20 billion, an increase of 6.62% compared to the previous year's 1.13 billion. Earnings were 182.92 million, a decrease of -10.99%.